INmune Bio prioritizes CORDStrom for recessive dystrophic epidermolysis bullosa

INmune Bio has announced plans to seek approval for its treatment CORDStrom, aimed at a serious skin condition called recessive dystrophic epidermolysis bullosa (RDEB). This development comes after positive results from trials conducted by independent researchers. Investors have not focused much on CORDStrom lately. However, there is growing anticipation regarding the treatment’s potential. The company is also looking ahead to results related to Alzheimer's disease, which could further influence investor interest. As the approval process unfolds, stakeholders are paying close attention to INmune Bio's progress. The developments could play a significant role in the company's future and its impact on patients suffering from these conditions.